A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer-Reference-Cited by-同舟云学术

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer

Published:2019-10-14 Issue:1 Volume:23 Page:184-193
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Ross Ashley E.,Hurley Paula J.,Tran Phuoc T.^ORCID,Rowe Steven P.,Benzon Benjamin,Neal Tanya O’,Chapman Carolyn,Harb Rana,Milman Yelena,Trock Bruce J.,Drake Charles G.,Antonarakis Emmanuel S.

Funder

Prostate Cancer Foundation

Merck

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-019-0176-8.pdf

Reference37 articles.

1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–17.

2. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.

3. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–51.

4. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–104.

5. Topalian SL. Targeting immune checkpoints in cancer therapy. JAMA. 2017;318:1647–8.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanomedicines in diagnosis and treatment of prostate cancers: an updated review;Frontiers in Bioengineering and Biotechnology;2024-08-21

2. Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study;European Urology Oncology;2024-07

3. Current Treatment Paradigms and Clinical Outcomes in Oligometastatic Prostate Cancer Patients: A Targeted Literature Review;European Urology Oncology;2024-07

4. Current evidence on local therapy in oligometastatic prostate cancer;Current Opinion in Urology;2024-02-01

5. Synergizing Thermal Ablation Modalities with Immunotherapy: Enough to Induce Systemic Antitumoral Immunity?;Journal of Vascular and Interventional Radiology;2024-02